This company listing is no longer active
DEST Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Destiny Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.03 |
| 52 Week High | UK£0.84 |
| 52 Week Low | UK£0.02 |
| Beta | 0.22 |
| 1 Month Change | -7.69% |
| 3 Month Change | -81.54% |
| 1 Year Change | -93.75% |
| 3 Year Change | -97.59% |
| 5 Year Change | -92.21% |
| Change since IPO | -98.62% |
Recent News & Updates
Recent updates
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Jan 12
Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans
Sep 26We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully
May 26Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth
Feb 01Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
Aug 05Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Apr 16What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?
Feb 11
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Nov 30Shareholder Returns
| DEST | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -14.3% | -5.1% | -2.2% |
| 1Y | -93.8% | -24.5% | 2.4% |
Return vs Industry: DEST underperformed the UK Biotechs industry which returned -22.1% over the past year.
Return vs Market: DEST underperformed the UK Market which returned 7.3% over the past year.
Price Volatility
| DEST volatility | |
|---|---|
| DEST Average Weekly Movement | 35.6% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DEST's share price has been volatile over the past 3 months.
Volatility Over Time: DEST's weekly volatility has increased from 21% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 15 | Chris Tovey | www.destinypharma.com |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.
Destiny Pharma plc Fundamentals Summary
| DEST fundamental statistics | |
|---|---|
| Market cap | UK£4.55m |
| Earnings (TTM) | -UK£5.66m |
| Revenue (TTM) | UK£831.55k |
3.5x
P/S Ratio-0.5x
P/E RatioIs DEST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEST income statement (TTM) | |
|---|---|
| Revenue | UK£831.55k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£831.55k |
| Other Expenses | UK£6.49m |
| Earnings | -UK£5.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 100.00% |
| Net Profit Margin | -680.30% |
| Debt/Equity Ratio | 0% |
How did DEST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/14 13:46 |
| End of Day Share Price | 2024/08/12 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Destiny Pharma plc is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian White | Cantor Fitzgerald Europe |
| Nathaniel Calloway | Edison Investment Research |
| Brian White | Shore Capital Group Ltd |